Odyssey Therapeutics, Inc. ODTX
19.17 USD -0.19 (-0.99%)
As ofNov 17, 2026, 10:02 AM EST
18.91 Day range 19.71
15.10 52-week range 29.05
- YTD
- +16.73%
- 1 year
- +16.73%
News
benzinga.com Odyssey Therapeutics Publishes Paper Titled 'TNFR2 agonism increases tissue and effector Treg cells In Journal Of Immunology Odyssey Therapeutics, Inc. (Nasdaq: ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and
globenewswire.com Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism “Cutting Edge” article demonstrates that compared with IL-2, TNFR2 agonism promotes tissue-directed regulatory T-cell differentiation and lineage stability, as well as reduces autoimmune inflammation…benzinga.com HC Wainwright & Co. Assumes Odyssey Therapeutics at Buy, Announces Price Target of $40 HC Wainwright & Co. analyst Joseph Pantginis assumes Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $40.
benzinga.com Odyssey Therapeutics Q3 EPS $(1.10) Misses $(1.08) Estimate Odyssey Therapeutics (NASDAQ:ODTX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.08) by 1.85 percent.
